Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Pharmacol. 2005 Jun;5(3):303-7.

    Myasthenia gravis: emerging new therapy options.

    Source

    Department of Neurology, Geriatrics and Palliative Care, General Hospital, Grosse Parower St 47-53, Stralsund, 18410 Germany. j.sieb@klinikum-stralsund.de

    Abstract

    Myasthenia gravis is probably the most thoroughly understood of all human autoimmune diseases. The basic mechanism of the disease is an antibody-mediated autoimmune attack that decreases the acetylcholine receptor density at the neuromuscular junction. Current therapies aim to restore the available acetylcholine receptors, deplete the autoantibodies or suppress the immune system. Prolonged drug treatment is required, but this carries a potential risk of severe adverse effects. Therefore, the ideal treatment for myasthenia would eliminate the abnormal autoimmune response without interfering with the immune system.

    PMID:
    15907918
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk